<DOC>
	<DOCNO>NCT02646540</DOCNO>
	<brief_summary>The purpose study test use tolvaptan ( commercial name Samsca ) give addition intravenous ( IV ) diuretic early episode acute heart failure . It compare high dose IV diuretic alone use metolazone addition IV diuretic . The investigator look see improvement symptom outcomes person acute heart failure .</brief_summary>
	<brief_title>AiDing Diuresis wIth Tolvaptan ( ADD-IT )</brief_title>
	<detailed_description>This single-center , randomize trial ass effect 30 mg daily tolvaptan give concomitantly home dose diuretic ( Lasix equivalent ) intravenously ( IV ) versus 5mg daily metolazone give concomitantly home dose diuretic ( Lasix equivalent ) IV , versus 2.5 time home dose diuretic ( Lasix equivalent ) IV participant hospitalize acutely decompensated heart failure ( ADHF ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Metolazone</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<criteria>Participants hospitalize worsen acute heart failure randomize within 36 hour initial presentation New York Heart Association ( NYHA ) Class III IV admission hospital least 1 month history treat heart failure Able understand content willing provide write informed consent The participant must sign extracellular volume expansion , define two follow four sign symptom : sign RHF ( right heart failure ) ( jugular venous distention , pit edema , ( â‰¥1+ ) , ascites and/or sign LHF ( left heart failure ) ( pulmonary congestion chest xray , pulmonary rale ) Brain Natriuretic Peptide ( BNP ) &gt; 450 serum sodium &lt; 140 mEq/L Positive urine pregnancy test woman child bear potential Inability provide write informed consent Cardiac surgery within 60 day prior study randomization Acute Coronary Syndrome ( ACS ) percutaneous coronary intervention within 30 day prior study randomization Planned revascularization procedure , cardiac mechanical support implantation , cardiac transplantation , cardiac surgery within 30 day follow study randomization Planned electrophysiologic ( EP ) device implantation within 7 day follow study randomization Subjects cardiac mechanical support Co morbid condition expect survival less six month History cerebrovascular accident within last 30 day Hemodynamically significant uncorrected primary cardiac valvular disease Hypertrophic cardiomyopathy ( obstructive nonobstructive ) Uncorrected thyroid disease , active myocarditis know amyloid cardiomyopathy History primary significant liver disease acute hepatic failure , define 3x upper limit normal ( ULN ) Chronic uncontrolled diabetes mellitus Hemoglobin A1C &gt; 10 % Supine systolic arterial blood pressure &lt; 90 mmHg Serum creatinine &gt; 3.5 mg/dL undergoing dialysis Hemoglobin &lt; 9 g/dL History hypersensitivity and/or idiosyncratic reaction benzazepine derivative ( benazepril ) Inability take oral medication Participation another clinical drug device trial last dose drug within past 30 day investigational medical device currently implant Previous exposure tolvaptan within 7 day prior randomization Subjects refractory , endstage , heart failure define subject appropriate candidate specialize treatment strategy , ventricular assist device , continuous positive IV inotropic therapy , hospice care Ultrafiltration within 7 day prior randomization plan . Active gout</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>